[ad_1]
For sufferers with relapsed or refractory a number of myeloma (RRMM), triplet remedy of belantamab mafodotin (belamaf) plus bortezomib and dexamethasone (BVd) improves outcomes, with an appropriate security profile, in response to a examine introduced throughout the February 2024 session of the American Society for Scientific Oncology Plenary Collection.
Maria-Victoria Mateos, Ph.D., from the Hospital Universitario de Salamanca in Spain, and colleagues carried out a randomized, section III head-to-head trial to look at the efficacy and security of BVd versus triplet standard-of-care therapy (daratumumab, bortezomib, and dexamethasone [DVd]) for sufferers with RRMM. A complete of 494 sufferers with a number of prior strains of remedy had been randomly allotted to BVd or DVd (243 and 251, respectively); the first finish level was impartial evaluate committee-assessed progression-free survival (PFS).
The researchers discovered that the median PFS was 36.6 and 13.4 months within the BVd and DVd arms, respectively, after a median follow-up of 28.2 months (hazard ratio, 0.41). General survival information had been 29 p.c mature; median overall survival was not reached in both arm (hazard ratio, 0.57).
The general response price was 82.7 and 71.3 p.c for BVd and DVd, respectively. All sufferers skilled a number of opposed occasion; 90 and 67 p.c of sufferers, respectively, within the BVd and DVd arms reported grade 3/4 treatment-related opposed occasions, and 50 and 37 p.c, respectively, reported critical opposed occasions.
“The DREAMM-7 findings display that BVd improved outcomes for sufferers with relapsed or refractory a number of myeloma whereas additionally having a manageable security profile,” Mateos mentioned in an announcement. “These outcomes help BVd triplet remedy as a possible new normal of care possibility for these sufferers.”
One creator disclosed ties to pharmaceutical firms, together with GlaxoSmithKline, which manufactures belamaf and funded the examine.
Extra data:
Press Release
Copyright © 2024 HealthDay. All rights reserved.
Quotation:
Triplet remedy together with belamaf prolongs survival in a number of myeloma (2024, February 10)
retrieved 10 February 2024
from https://medicalxpress.com/information/2024-02-triplet-therapy-belamaf-prolongs-survival.html
This doc is topic to copyright. Aside from any truthful dealing for the aim of personal examine or analysis, no
half could also be reproduced with out the written permission. The content material is supplied for data functions solely.
[ad_2]
Source link
Discussion about this post